Evidence map›Paper›PMID 36750858›Full record

Trial reportRadiation oncology (London, England)2023

Extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9).

Dashan Ai, Yun Chen, Qi Liu, Jiaying Deng, Xiaofei Zhang, Junhua Zhang, Li Chu, Jingyi Shen, Longfei Ma, Yawei Zhang and 4 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Radiation oncology (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02916511 (Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02916511 phase2completednot on this map

Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma

TypeinterventionalSponsorFudan UniversityRan2016 to 2023Enrolled70ConditionsEsophageal Squamous Cell CarcinomaArmsPaclitaxel, Carboplatin, Radiotherapy
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Dashan AiDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yun ChenDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Qi LiuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Jiaying DengDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Xiaofei ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Junhua ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Li ChuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Jingyi ShenDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Longfei MaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Yawei ZhangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Haiquan ChenDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Longsheng MiaoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. miaolongsheng@126.com.
Kuaile ZhaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. kuaile_z@fudan.edu.cn.
Jiaqing XiangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. j.q.xiang@hotmail.com.
Shanghai Medical College of Fudan University · CNFudan University Shanghai Cancer Center · CN

Funding

National Key Research and Development Program of China MOST-2016YFC1303200National Natural Science Foundation of China 21172043
6 · The paper itself

Abstract

backgroundTo compare the efficacy and safety of postoperative extensive target volume irradiation with elevated radiation dose and concurrent chemotherapy with radiotherapy only for the postoperative treatment of esophageal squamous cell carcinoma.

methodsThis trial was a single-arm phase II trial. Patients who underwent a radical transthoracic resection with negative margins within 3 months and histologically confirmed esophageal squamous cell carcinoma (pT3-4N0M0 or pTxN + M0, AJCC 7th) were eligible for this study. Postoperative radiotherapy was performed at a total dose of 45 Gy in 25 fractions with clinical target volumes of the tumor bed, anastomosis, bilateral supraclavicular, mediastinal, left gastric and celiac trunk lymph node areas. Five cycles of weekly TC (paclitaxel 50 mg/m

resultsA total of 70 patients were enrolled from 2016 to 2018. The 2-year local control rate was 87.9% (95% CI: 83.3-92.3) in this study, which achieved the hypothesized 2-year local control rate of at least 83%. Overall survival, disease free survival, local-regional recurrence free survival and distant metastasis free survival in this study were also longer than those in previous ESO-Shanghai 8 study while most toxicities were increased and two patients in this study died of radiation pneumonitis.

conclusionsPostoperative extensive target volume irradiation with elevated radiation dose and concurrent chemotherapy was effective. Treatment related toxicity was increased due to higher treatment intensity. Trial registration clinicaltrials.gov: NCT02916511.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyChinaCisplatinHumansPaclitaxelCisplatinPaclitaxelChemotherapyEsophageal cancerPostoperative treatmentRadiotherapy

Identifiers

PMID36750858
PMCPMC9903423
OpenAlexW4319442165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.